Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modeling approach Dawn K.

Slides:

Advertisements

Similar presentations

Hepatitis B & Hepatitis C in HIV

Advertisements

Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Adriana Weinberg, MD University of Colorado Denver.

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.

Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.

Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.

HIV AND HIV MUTANTS E. Chigidi and E. Lungu University of Botswana Private Bag 0022 Gaborone, Botswana.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

PROMISE Introduction to PROMISE Protocol May 6, 2009.

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College.

Potential role of PEP, PrEP and ART for HIV Prevention among Men who have Sex with Men Frits van Griensven, PhD, MPH Division of HIV/AIDS Prevention US.

Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.

HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study MC Thigpen,

Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot.

Characteristics and Oral PrEP Adherence in the TDF2 Open-Label Extension in Botswana Henderson FL 1, Taylor AW 1, Chirwa LI 2,Williams TS 1,3, Borkowf.

Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.

What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.

Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.

Global HIV Resistance: The Implications of Transmission

Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.

Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.

ARV-based Microbicides and Resistance Jeanne Marrazzo, M.D., M.P.H. University of Washington John Mellors, M.D. University of Pittsburgh.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

A PEP and PrEP Update Jeffrey D. Klausner, MD, MPH Black AIDS Institute-UCLA African-American University September 2014 Special thanks to Raphael Landovitz,

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.

Overview of Microbicide Trials Issues and Challenges.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Michael Hughes, MD Assistant Clinical Professor UCR Eisenhower Medical Associates.

ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.

Enfuvirtide for Drug-Resistant HIV Infection in North and South America Simon R. Bababeygy.

National Prevalence of Transmitted HIV Drug Resistance in Swaziland in 2011 R. Suzanne Beard, Ph.D. Abstract/poster: TUPDC0103.

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.

Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

BRADFORD BRIGGS & NIKE JACKSON. BRADFORD BRIGGS Prevention Toolbox.

Track C: Epidemiology, prevention and prevention research Quarraisha Abdool Karim (Chief Rapporteur) Team: Marian Swart, Ken Mayer, Cheryl Baxter, Ayesha.

HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,

Understanding the Rationale of the 2015 WHO Guidelines on PrEP IAS Satellite Session Heather Watts M.D. Office of the Global AIDS Coordinator July 18,

Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.

Benefits of pre-exposure prophylaxis relative to drug resistance risk

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

Module 4 (e) Pregnancy and Breast Feeding

On behalf of The MTN-020/ASPIRE Study Team

PrEP as an HIV Prevention Tool in Queer Communities of Color: Barriers and Opportunities BACKGROUND Joanne Stekler, MD MPH.

On Demand PrEP for Men at High Risk for HIV IPERGAY

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Pre-exposure Prophylaxis (PrEP)

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Quarraisha Abdool Karim, PhD

PrEP: A Case-by-Case Approach

PrEP in Women: Unique Considerations and Strategies

PrEP Pre-Exposure Prophylaxis

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

HIV Resistance in the Context of PrEP

Bob Holtkamp, Director of Prevention & Outreach

Presentation transcript:

Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modeling approach Dawn K. Smith, Poloko Kebaabetswe, Kisanga Disasi, Douglas Fleming, Lynn Paxton, and Margarett Davis

PrEP Trials Concerns raised about the population effects of daily oral antiretroviral prophylaxis if found to be substantially but not completely effective Concerns raised about the population effects of daily oral antiretroviral prophylaxis if found to be substantially but not completely effective –Availability and cost –Behavioral disinhibition –Increased prevalence of resistant virus complicating treatment

Phase II/III 600 men and 600 women 600 men and 600 women Randomize 1:1 to TDF or placebo daily Randomize 1:1 to TDF or placebo daily Follow monthly for at least 12 months Follow monthly for at least 12 months Phase IIPhase III Safety Interim Final Confirm SafetyDetermine if TDF works

MASA ARV Treatment Sites

How large a problem is TDF resistance likely to be? Participants could become infected with a virus with TDF resistance mutation(s) by: Participants could become infected with a virus with TDF resistance mutation(s) by: –Exposure to virus from an HIV-infected person with a mutated virus –Acquisition of wild-type virus and development of resistance mutations while on PrEP with undetected infection

Development of resistance TDF dispensed monthly TDF dispensed monthly HIV testing done monthly HIV testing done monthly So max time on TDF monotherapy while infection undetected is 1-2 months So max time on TDF monotherapy while infection undetected is 1-2 months

Resistance in trial participants? An estimate of the numbers DEVELOP RESISTANCE DEVELOP RESISTANCE 1200 on study 1200 on study

Resistance in trial participants? An estimate of the numbers DEVELOP RESISTANCE DEVELOP RESISTANCE 1200 on study 1200 on study 600 on TDF 600 on TDF

Resistance in trial participants? An estimate of the numbers DEVELOP RESISTANCE DEVELOP RESISTANCE 1200 on study 1200 on study 600 on TDF 600 on TDF 15 (2.5%) infected 15 (2.5%) infected

Resistance in trial participants? An estimate of the numbers DEVELOP RESISTANCE DEVELOP RESISTANCE 1200 on study 1200 on study 600 on TDF 600 on TDF 15 (2.5%) infected 15 (2.5%) infected If 1% develop resistance If 1% develop resistance < 1 person infected with resistant virus < 1 person infected with resistant virus

Resistance in trial participants? An estimate of the numbers INFECTED BY A RESISTANT VIRUS INFECTED BY A RESISTANT VIRUS 330,000 HIV+ 330,000 HIV+

Resistance in trial participants? An estimate of the numbers INFECTED BY A RESISTANT VIRUS INFECTED BY A RESISTANT VIRUS 330,000 HIV+ 330,000 HIV+ 45,000 on HAART 45,000 on HAART

Resistance in trial participants? An estimate of the numbers INFECTED BY A RESISTANT VIRUS INFECTED BY A RESISTANT VIRUS 330,000 HIV+ 330,000 HIV+ 45,000 on HAART 45,000 on HAART 20,000 in Gabs/FT 20,000 in Gabs/FT

Resistance in trial participants? An estimate of the numbers INFECTED BY A RESISTANT VIRUS INFECTED BY A RESISTANT VIRUS 330,000 HIV+ 330,000 HIV+ 45,000 on HAART 45,000 on HAART 20,000 in Gabs/FT 20,000 in Gabs/FT 3060 (15.3%) detectable virus 3060 (15.3%) detectable virus

Resistance in trial participants? An estimate of the numbers INFECTED BY A RESISTANT VIRUS INFECTED BY A RESISTANT VIRUS 330,000 HIV+ 330,000 HIV+ 45,000 on HAART 45,000 on HAART 20,000 in Gabs/FT 20,000 in Gabs/FT 3060 (15.3%) detectable virus 3060 (15.3%) detectable virus 573 (3/16, 19%) with K65R 573 (3/16, 19%) with K65R

Resistance in trial participants? An estimate of the numbers INFECTED BY A RESISTANT VIRUS INFECTED BY A RESISTANT VIRUS 330,000 HIV+ 330,000 HIV+ 45,000 on HAART 45,000 on HAART 20,000 in Gabs/FT 20,000 in Gabs/FT 3060 (15.3%) detectable virus 3060 (15.3%) detectable virus 573 (3/16, 19%) with K65R 573 (3/16, 19%) with K65R Considering Considering –Selection of partners –Per act transmission rate –~0 infected with resistant virus

Resistance in trial participants? An estimate of the numbers DEVELOP RESISTANCE DEVELOP RESISTANCE 1200 on study 1200 on study 600 on TDF 600 on TDF 15 (2.5%) infected 15 (2.5%) infected If 1% develop resistance If 1% develop resistance < 1 person infected with resistant virus < 1 person infected with resistant virus INFECTED BY A RESISTANT VIRUS INFECTED BY A RESISTANT VIRUS 330,000 HIV+ 330,000 HIV+ 45,000 on HAART 45,000 on HAART 20,000 in Gabs/FT 20,000 in Gabs/FT 3060 (15.3%) detectable virus 3060 (15.3%) detectable virus 573 (3/16, 19%) with K65R 573 (3/16, 19%) with K65R Considering Considering –Selection of partners –Per act transmission rate –~0 infected with resistant virus

Measuring Resistance All seroconverters continue in follow-up All seroconverters continue in follow-up Genotypic and phenotypic resistance testing will be done for all seroconverters Genotypic and phenotypic resistance testing will be done for all seroconverters

Trial change Phase II still underway with TDF alone Phase II still underway with TDF alone Phase III will be done with TDF+FTC daily Phase III will be done with TDF+FTC daily –Macaque data suggesting better efficacy –PMTCT data suggesting 2 drugs more efficacious than 1 –Few added side effects –Little additional cost –Still one pill per day

Conclusions Most drug-resistant virus will be generated in the ARV treatment population Most drug-resistant virus will be generated in the ARV treatment population The TDF PrEP trials will result in few (if any) additional infections with resistant virus The TDF PrEP trials will result in few (if any) additional infections with resistant virus Treatment alternatives are available in Botswana for trial seroconverters if they acquire resistant virus Treatment alternatives are available in Botswana for trial seroconverters if they acquire resistant virus The switch to two drugs within the PrEP trial will further lower the risk of infections with resistant virus within trial participants The switch to two drugs within the PrEP trial will further lower the risk of infections with resistant virus within trial participants

Contact "The findings and conclusions in this presentation have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy." Dawn K. Smith x210

Study 903: Phenotypic Susceptibility of NRTIs in Presence of K65R (n=8) Fully Susceptible Intermediate Susceptibility Resistant Fold Change Phenosense Assay (ViroLogic cut-off)